title: A novel formulation of an ophthalmic beta-adrenoceptor antagonist.
abstract: To minimize ocular discomfort while maintaining efficacy, a delivery system for a topical cardioselective beta-adrenoceptor antagonist, betaxolol was developed. Betaxolol was formulated at 0.25% concentration in a cationic exchange resin, as a suspension. A polyacrylic acid polymer was added to increase viscosity and to increase residence time in the cul-de-sac. No significant settling was observed throughout a four-week observation period. Thus, resuspension of the formulation by frequent shaking was not required for uniformity. In rabbits, the ocular bioavailability of 0.25% betaxolol suspension was equivalent to that of 0.5% betaxolol solution.
authors.affiliation: Department of Ophthalmology, School of Medicine, University of California, San Diego 92093.
authors.forename: R N
authors.initials: RN
authors.lastname: Weinreb
authors.forename: R
authors.initials: R
authors.lastname: Jani
mesh_terms: D000818:Animals; D015784:Betaxolol / Q000008:administration & dosage*; D009883:Ophthalmic Solutions; D011817:Rabbits; D013535:Suspensions
chemical_list: D009883:Ophthalmic Solutions; D013535:Suspensions; D015784:Betaxolol